Literature DB >> 22740976

Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Giuliana Cássia Morrone Taromaru1, Vilmar Marques DE Oliveira, Maria Antonieta Longo Galvão Silva, Wagner Ricardo Montor, Fabio Bagnoli, José Francisco Rinaldi, Tsutomu Aoki.   

Abstract

The objective of this study was to evaluate the correlation between cyclooxygenase-2 (COX-2) and markers of cell proliferation and apoptosis, including, Bcl-2, Bax, Ki-67 and the type I insulin-like growth factor (IGF) receptor (IGF1-R) in ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC), present in the same surgical specimen. A total of 110 cases were evaluated using tissue microarrays. Cases were classified in scores from 0 to 3 according to pre-defined methods. The results showed that the positivity rates were COX-2 in 87% of cases in DCIS and IDC; Bcl-2 in 55% of cases in DCIS and IDC; Bax in 23% of cases in IDC and 19% in DCIS, IGF-1 in 24% of cases in DCIS and IDC; and Ki-67 in 81% of cases in DCIS and IDC. We also observed a positive correlation between the expression of COX-2 and IGF1-R (p=0.045). Our results demonstrate a positive correlation between the expression of COX-2 and IGF1-R in DCIS and IDC, demonstrating that they are involved in breast cancer carcinogenesis. Further studies are required to prove the effectiveness of COX-2 and IGF1-R inhibitors for the prevention and treatment of breast cancer, as well as to explain their mechanism of action.

Entities:  

Year:  2011        PMID: 22740976      PMCID: PMC3362482          DOI: 10.3892/ol.2011.532

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  50 in total

1.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Authors:  Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

2.  Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.

Authors:  Katrine L Henriksen; Birgitte B Rasmussen; Anne E Lykkesfeldt; Susann Møller; Bent Ejlertsen; Henning T Mouridsen
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

3.  COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.

Authors:  G Perrone; D Santini; B Vincenzi; M Zagami; A La Cesa; A Bianchi; V Altomare; A Primavera; C Battista; A Vetrani; G Tonini; C Rabitti
Journal:  Histopathology       Date:  2005-05       Impact factor: 5.087

4.  Tamoxifen for breast cancer among hysterectomised women.

Authors:  U Veronesi; P Maisonneuve; V Sacchini; N Rotmensz; P Boyle
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

5.  Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.

Authors:  Jeong Yun Shim; Hee Jung An; Yong Hee Lee; Seung Ki Kim; Kyong Po Lee; Kyong Sik Lee
Journal:  Mod Pathol       Date:  2003-12       Impact factor: 7.842

Review 6.  Tpl-2/Cot and COX-2 in breast cancer.

Authors:  Zuzana Krcova; Jiri Ehrmann; Veronika Krejci; Aris Eliopoulos; Zdenek Kolar
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2008-06       Impact factor: 1.245

7.  The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer.

Authors:  Paul J Mintz; Nagy A Habib; Louise J Jones; Georgios Giamas; Jacqueline S Lewis; Rebecca L Bowen; R Charles Coombes; Justin Stebbing
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

8.  Bax expression in untreated breast cancer: an immunocytometric study of 255 cases.

Authors:  F Martínez-Arribas; E Martín-Garabato; I Zapardiel; J Sánchez; A R Lucas; A Tejerina; J Schneider
Journal:  Anticancer Res       Date:  2008 Sep-Oct       Impact factor: 2.480

9.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

Authors:  Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

10.  Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2.

Authors:  Valérie Benoit; Biserka Relic; Xavier de Leval Xd; Alain Chariot; Marie-Paule Merville; Vincent Bours
Journal:  Oncogene       Date:  2004-02-26       Impact factor: 9.867

View more
  4 in total

1.  Chemopreventive effects of curcumin on chemically induced mouse skin carcinogenesis in BK5.insulin-like growth factor-1 transgenic mice.

Authors:  Hyoseon Kim; Jeongeun Park; Ka-Hee Tak; So Young Bu; Eunjung Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-07-16       Impact factor: 2.416

2.  MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells.

Authors:  J S Huang; M E Egger; W E Grizzle; L R McNally
Journal:  Biotech Histochem       Date:  2013-02-04       Impact factor: 1.718

Review 3.  The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.

Authors:  Arthur Adams; Aram S A van Brussel; Jeroen F Vermeulen; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Sjoerd G Elias
Journal:  BMC Cancer       Date:  2013-11-10       Impact factor: 4.430

4.  Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.

Authors:  Sheng Yang; Hui Han
Journal:  Oncol Lett       Date:  2014-07-30       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.